April 26, 2024
Astellas faced an 80% plunge in its operating profit for FY2023, affected by the acquisition of Iveric Bio and the amortization of intangible assets for Izervay (avacincaptad pegol), an age-related macular degeneration (AMD) treatment obtained from the US-based biotech. According...read more